Reichart P A, Philipsen H P, Sonner S
Abteilung für Oralchirurgie und Zahnärztliche Röntgenologie, Zentrum für Zahnmedizin, Universitätsklinikum Charité, Berlin, Germany.
Eur J Cancer B Oral Oncol. 1995 Mar;31B(2):86-99. doi: 10.1016/0964-1955(94)00037-5.
Available literature on ameloblastoma of the jaw was reviewed, including publications from 1960 to 1993, and compared to the latest larger review, published by Small and Waldron in 1955. The average age of patients with ameloblastoma is 36 years. In developing countries ameloblastomas occur in younger patients. Men and women are equally affected. Women are 4 years younger than men when ameloblastomas first occur, and the tumours appear to be larger in females. Dominant clinical symptoms such as painless swelling and slow growth are non-characteristic. The ratio of ameloblastoma of the mandible to maxilla is 5 to 1. Ameloblastomas of the mandible occur 12 years earlier than those of the maxilla. Ameloblastomas occur most frequently in the molar region of the mandible. In Blacks, ameloblastomas occur more frequently in the anterior region of the jaws. Radiologically, 50% of ameloblastomas appear as multilocular radiolucent lesions with sharp delineation. Histologically, one-third are plexiform, one-third follicular; other variants such as acanthomatous ameloblastoma occur in older patients. Two percent of ameloblastomas are peripheral tumours. Unicystic ameloblastomas occurring in younger patients have been found in 6%. Detailed data on 345 patients with ameloblastoma were evaluated for clarification of therapeutic approaches. Chemotherapy and radiation seem to be contraindicated. Ameloblastomas of the maxilla should be treated as radically as possible, ameloblastomas of the mandible should also be treated radically. However, ameloblastomas which radiologically appear as unilocular lesions may be treated conservatively (enucleation, curettage), whenever all areas of the cystic lumen are controllable intraoperatively. Unicystic ameloblastomas occurring in patients 15 years younger than those with multisystic ameloblastoma may be treated conservatively except in cases with invasion of epithelium into the cyst wall. Different recurrence rates have been found for histological variants of the ameloblastoma. Follicular ameloblastomas appear to recur more often than the plexiform type. Unicystic ameloblastomas reveal lower recurrence rates than "non-unicystic" ameloblastomas. The peripheral type of ameloblastoma may be excised, since conservative therapy results in low recurrence rates. Postoperative follow-up is most important in the therapy of ameloblastoma, because more than 50% of all recurrences occur within 5 years postoperatively.
回顾了1960年至1993年有关颌骨成釉细胞瘤的现有文献,并与Small和Waldron于1955年发表的最新大规模综述进行了比较。成釉细胞瘤患者的平均年龄为36岁。在发展中国家,成釉细胞瘤多见于年轻患者。男性和女性受影响的几率相同。成釉细胞瘤首次发病时,女性比男性年轻4岁,且女性的肿瘤似乎更大。无痛性肿胀和生长缓慢等主要临床症状并无特异性。下颌骨与上颌骨成釉细胞瘤的比例为5比1。下颌骨成釉细胞瘤的发病时间比上颌骨早12年。成釉细胞瘤最常发生在下颌骨的磨牙区。在黑人中,成釉细胞瘤更常发生在颌骨的前部。在放射学上,50%的成釉细胞瘤表现为边界清晰的多房性透射性病变。在组织学上,三分之一为丛状型,三分之一为滤泡型;其他变体如棘皮瘤型成釉细胞瘤多见于老年患者。2%的成釉细胞瘤为外周型肿瘤。6%的成釉细胞瘤为发生于年轻患者的单囊性成釉细胞瘤。对345例成釉细胞瘤患者的详细数据进行了评估,以明确治疗方法。化疗和放疗似乎是禁忌的。上颌骨成釉细胞瘤应尽可能进行根治性治疗,下颌骨成釉细胞瘤也应进行根治性治疗。然而,对于放射学上表现为单房性病变的成釉细胞瘤,只要术中能控制囊腔的所有区域,可进行保守治疗(摘除、刮除)。发生于比多囊性成釉细胞瘤患者小15岁的患者中的单囊性成釉细胞瘤,除上皮侵入囊壁的情况外,可进行保守治疗。成釉细胞瘤的不同组织学变体的复发率不同。滤泡型成釉细胞瘤的复发似乎比丛状型更常见。单囊性成釉细胞瘤的复发率低于“非单囊性”成釉细胞瘤。外周型成釉细胞瘤可切除,因为保守治疗的复发率较低。术后随访在成釉细胞瘤的治疗中最为重要,因为超过50%的复发发生在术后5年内。